Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Kaat van Casteren"'
Autor:
Kelly Dufraing, Kaat Van Casteren, Joke Breyne, Nicky D’Haene, Claude Van Campenhout, Sara Vander Borght, Karen Zwaenepoel, Etienne Rouleau, Ed Schuuring, Jan von der Thüsen, Elisabeth Dequeker
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-20 (2022)
Abstract Background For patients with non-small cell lung cancer (NSCLC), targeted therapies are becoming part of the standard treatment. It is of question which information the clinicians provide on test requests and how the laboratories adapt test
Externí odkaz:
https://doaj.org/article/005a0612409243a0b303ce9ae8fd9332
Autor:
Jennifer A. Fairley, Melanie H. Cheetham, Simon J. Patton, Etienne Rouleau, Marc Denis, Elisabeth M. C. Dequeker, Ed Schuuring, Kaat van Casteren, Francesca Fenizia, Nicola Normanno, Zandra C. Deans
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-12 (2022)
Abstract Background Circulating cell free DNA (cfDNA) testing of plasma for EGFR somatic variants in lung cancer patients is being widely implemented and with any new service, external quality assessment (EQA) is required to ensure patient safety. An
Externí odkaz:
https://doaj.org/article/2db9d6d558434af387830fabde90da75
Autor:
Cleo Keppens, Elisabeth M. C. Dequeker, Etienne Rouleau, Nils ’t Hart, Lukas Bubendorf, Kelly Dufraing, Céline Garrec, Paul Guéguen, Aude Lamy, Antonio Marchetti, Patrick Pauwels, Ales Ryska, Véronique Tack, Luigi Tornillo, Kaat Van Casteren, Jan H. von der Thüsen, Karen Zwaenepoel, Birgit Lissenberg-Witte, Erik Thunnissen, Ed Schuuring
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-11 (2020)
Abstract Background Correct identification of the EGFR c.2369C>T p.(Thr790Met) variant is key to decide on a targeted therapeutic strategy for patients with acquired EGFR TKI resistance in non-small cell lung cancer. The aim of this study was to eval
Externí odkaz:
https://doaj.org/article/a6a32d9ed52f4d1a8db1c8899b5c04ee
Autor:
Elien Augustus, Kaat Van Casteren, Laure Sorber, Peter van Dam, Geert Roeyen, Marc Peeters, Alex Vorsters, An Wouters, Jo Raskin, Christian Rolfo, Karen Zwaenepoel, Patrick Pauwels
Publikováno v:
PLoS ONE, Vol 15, Iss 4, p e0231058 (2020)
Although liquid biopsies offer many advantages over tissue biopsies, they are not yet standard practice. An important reason for the lack of implementation is the unavailability of well standardized techniques and guidelines, especially for pre-analy
Externí odkaz:
https://doaj.org/article/a91766e399ec43e68b52608935c34cd3
Autor:
Laure Sorber, Karen Zwaenepoel, Julie Jacobs, Koen De Winne, Sofie Goethals, Pablo Reclusa, Kaat Van Casteren, Elien Augustus, Filip Lardon, Geert Roeyen, Marc Peeters, Jan Van Meerbeeck, Christian Rolfo, Patrick Pauwels
Publikováno v:
Cancers, Vol 11, Iss 4, p 458 (2019)
The combined analysis of circulating cell-free (tumor) DNA (cfDNA/ctDNA) and circulating cell-free (tumor) RNA (cfRNA/ctRNA) shows great promise in determining the molecular profile of cancer patients. Optimization of the workflow is necessary to ach
Externí odkaz:
https://doaj.org/article/0012f707ac684910bdfabb0f54feef2f
Autor:
Laure Sorber, Karen Zwaenepoel, Koen De Winne, Kaat Van Casteren, Elien Augustus, Julie Jacobs, Xiang Hua Zhang, Daniëlla Galdermans, Els De Droogh, Anneke Lefebure, Ann-Marie Morel, Erika Saenen, Frédérique Bustin, Ingel Demedts, Ulrike Himpe, Thierry Pieters, Paul Germonpré, Sofie Derijcke, Koen Deschepper, Jan P. Van Meerbeeck, Christian Rolfo, Patrick Pauwels
Publikováno v:
Cancers, Vol 10, Iss 9, p 290 (2018)
A multicenter study was performed to determine an optimal workflow for liquid biopsy in a clinical setting. In total, 549 plasma samples from 234 non-small cell lung cancer (NSCLC) patients were collected. Epidermal Growth Factor Receptor (EGFR) circ
Externí odkaz:
https://doaj.org/article/3d2d24e5088d4cc8ab397b2b98494751
Autor:
Karen Zwaenepoel, Kaat Van Casteren, Joke Breyne, Etienne Rouleau, Elisabeth Dequeker, Kelly Dufraing, Nicky D'Haene, Claude Van Campenhout, Ed Schuuring, Jan H. von der Thüsen, Sara Vander Borght
Publikováno v:
BMC Cancer, 22:736. BMC
BMC cancer
BMC Cancer, 22(1):736. BioMed Central Ltd.
BMC cancer
BMC Cancer, 22(1):736. BioMed Central Ltd.
Background For patients with non-small cell lung cancer (NSCLC), targeted therapies are becoming part of the standard treatment. It is of question which information the clinicians provide on test requests and how the laboratories adapt test conclusio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0d095f7c53f313d87f20504da8a0a8b0
https://research.rug.nl/en/publications/baa504ca-1487-4d15-989f-fc0641160a64
https://research.rug.nl/en/publications/baa504ca-1487-4d15-989f-fc0641160a64
Autor:
Ed Schuuring, Zandra C. Deans, Simon Patton, Nicola Normanno, Kaat Van Casteren, Cleo Keppens, Elisabeth Dequeker
Publikováno v:
The Journal of Molecular Diagnostics. 22:736-747
Liquid biopsies have emerged as a useful addition to tissue biopsies in molecular pathology. Literature has shown lower laboratory performances when a new method of variant analysis is introduced. This study evaluated the differences in variant analy
Autor:
Elien Augustus, Hans Prenen, Kaat Van Casteren, Karen Zwaenepoel, Geert Roeyen, Jan P. van Meerbeeck, Marc Peeters, Christian Rolfo, Filip Lardon, Patrick Pauwels, Julie Jacobs, Laure Sorber, Koen De Winne
Publikováno v:
Molecular Diagnosis & Therapy
Introduction The potential of circulating cell-free DNA (cfDNA) analysis as a liquid biopsy has led to the development of several specialized measuring tools. Interest in the (pre-)analytical conditions of the liquid biopsy workflow has increased ove
Autor:
Kaat Van Casteren, Karen Zwaenepoel, Aude Lamy, Elisabeth Dequeker, Nils A. 't Hart, Céline Garrec, Jan H. von der Thüsen, Paul Guéguen, Cleo Keppens, Luigi Tornillo, Véronique Tack, Lukas Bubendorf, Patrick Pauwels, Etienne Rouleau, Ed Schuuring, Birgit I. Lissenberg-Witte, Kelly Dufraing, Erik Thunnissen, Antonio Marchetti, Ales Ryska
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-11 (2020)
BMC Cancer
BMC cancer
Keppens, C, Dequeker, E M C, Rouleau, E, T'Hart, N, Bubendorf, L, Dufraing, K, Garrec, C, Guéguen, P, Lamy, A, Marchetti, A, Pauwels, P, Ryska, A, Tack, V, Tornillo, L, Van Casteren, K, Von Der Thüsen, J H, Zwaenepoel, K, Lissenberg-Witte, B, Thunnissen, E & Schuuring, E 2020, ' Sensitive detection methods are key to identify secondary EGFR c.2369C >T p.(Thr790Met) in non-small cell lung cancer tissue samples ', BMC Cancer, vol. 20, no. 1, 366 . https://doi.org/10.1186/s12885-020-06831-3
BMC Cancer, 20(1):366. BioMed Central Ltd.
BMC Cancer, 20(1):366. BMC
BMC Cancer, 20(1):366. BioMed Central
BMC Cancer
BMC cancer
Keppens, C, Dequeker, E M C, Rouleau, E, T'Hart, N, Bubendorf, L, Dufraing, K, Garrec, C, Guéguen, P, Lamy, A, Marchetti, A, Pauwels, P, Ryska, A, Tack, V, Tornillo, L, Van Casteren, K, Von Der Thüsen, J H, Zwaenepoel, K, Lissenberg-Witte, B, Thunnissen, E & Schuuring, E 2020, ' Sensitive detection methods are key to identify secondary EGFR c.2369C >T p.(Thr790Met) in non-small cell lung cancer tissue samples ', BMC Cancer, vol. 20, no. 1, 366 . https://doi.org/10.1186/s12885-020-06831-3
BMC Cancer, 20(1):366. BioMed Central Ltd.
BMC Cancer, 20(1):366. BMC
BMC Cancer, 20(1):366. BioMed Central
Background Correct identification of the EGFR c.2369C>T p.(Thr790Met) variant is key to decide on a targeted therapeutic strategy for patients with acquired EGFR TKI resistance in non-small cell lung cancer. The aim of this study was to evaluate the